PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 11.66M USD | Liabilities, Current |
| Cash and equivalents | 288.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.66M | $288.19M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $32.52M | $329.46M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $40.84M | $307.53M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $51.44M | $330.84M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $67.81M | $371.44M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $48.46M | $417.94M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $48.50M | $471.39M | (m) | $0.00 | (m) | (m) |
| 2024-09-30 | (m) | $46.42M | $519.26M | (m) | $0.00 | (m) | (m) |
| 2024-06-30 | (m) | $46.74M | $564.12M | (m) | $0.00 | (m) | (m) |
| 2024-03-31 | (m) | $43.27M | $546.51M | (m) | $0.00 | (m) | (m) |
| 2023-12-31 | (m) | $56.89M | $618.83M | (m) | $5.16M | (m) | (m) |
| 2023-09-30 | (m) | $53.37M | $670.90M | (m) | $5.16M | (m) | (m) |
| 2023-06-30 | (m) | $71.56M | $659.11M | (m) | $524.00K | (m) | (m) |
| 2023-03-31 | (m) | $48.88M | $686.18M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $50.15M | $710.41M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $50.60M | $495.63M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $40.11M | $508.80M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $36.50M | $542.99M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $33.45M | $579.09M | (m) | $0.00 | (m) | (m) |
| 2021-09-30 | (m) | $29.20M | $600.10M | (m) | $79.00K | (m) | (m) |
| 2021-06-30 | (m) | $52.90M | $399.83M | (m) | $3.00K | (m) | (m) |
| 2021-03-31 | (m) | $23.46M | $342.99M | (m) | $1.00K | (m) | (m) |
| 2020-12-31 | (m) | $25.85M | $295.38M | (m) | $15.00K | (m) | (m) |
| 2020-09-30 | (m) | $21.72M | $314.52M | (m) | $22.00K | (m) | (m) |
| 2020-06-30 | (m) | $18.54M | $333.94M | (m) | $56.00K | (m) | (m) |
| 2020-03-31 | (m) | $17.09M | $352.69M | (m) | $174.00K | (m) | (m) |
| 2019-12-31 | (m) | $17.71M | $375.72M | (m) | $68.00K | (m) | (m) |
| 2019-09-30 | (m) | $31.76M | $390.30M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $28.02M | $398.14M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $14.91M | $410.11M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $14.93M | $427.66M | (m) | $2.00K | (m) | (m) |
| 2018-09-30 | (m) | $23.63M | $451.51M | (m) | $0.00 | (m) | (m) |
| 2018-06-30 | (m) | $46.13M | $486.21M | (m) | $8.00K | (m) | (m) |
| 2018-03-31 | (m) | $35.55M | $429.04M | (m) | $12.00K | (m) | (m) |
| 2017-12-31 | (m) | $37.37M | $417.62M | (m) | $240.00K | (m) | (m) |
| 2017-09-30 | (m) | $39.26M | $456.06M | (m) | $220.00K | (m) | (m) |
| 2017-06-30 | (m) | $39.60M | $471.73M | (m) | $30.24M | (m) | (m) |
| 2017-03-31 | (m) | $33.68M | $506.55M | (m) | $271.00K | (m) | (m) |
| 2016-12-31 | (m) | $41.08M | $386.92M | (m) | $178.00K | (m) | (m) |
| 2016-09-30 | (m) | $36.91M | $408.57M | (m) | $409.00K | (m) | (m) |
| 2016-06-30 | (m) | $33.46M | $442.95M | (m) | $364.00K | (m) | (m) |
| 2016-03-31 | (m) | $23.23M | $474.25M | (m) | $1.00M | (m) | (m) |
| 2015-12-31 | (m) | $22.22M | $370.59M | (m) | $509.00K | (m) | (m) |
| 2015-09-30 | (m) | $18.56M | $387.80M | (m) | $814.00K | (m) | (m) |
| 2015-06-30 | (m) | $13.46M | $402.39M | (m) | $961.00K | (m) | (m) |
| 2015-03-31 | (m) | $9.54M | $279.86M | (m) | $1.36M | (m) | (m) |
| 2014-12-31 | (m) | $12.04M | $293.58M | (m) | $1.73M | (m) | (m) |
| 2014-09-30 | (m) | $9.97M | $306.15M | (m) | $967.00K | (m) | (m) |
| 2014-06-30 | (m) | $11.31M | $303.85M | (m) | $1.49M | (m) | (m) |
| 2014-03-31 | (m) | $8.96M | $195.05M | (m) | $2.16M | (m) | (m) |
| 2013-12-31 | (m) | $7.41M | $176.68M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $7.71M | $101.86M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $9.08M | $112.51M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $5.09M | $119.56M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.74M | $124.86M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |